GLPwatch
Papers (12034)
Page 199 of 201, ranked by citation count.
- [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
- Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.
- Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.
- Computational phenotyping of effort-based decision-making in type-2 diabetes on and off semaglutide.
- Early Generic Semaglutide in Canada-Implications for US Patients and Policy.
- Semaglutide Induces Oxidative Stress and Differentially Modulates mTOR-Dependent Growth and Invasion in Human Trophoblast Cell Models: Implications for Placental Function.
- GLP-1 receptor agonists in atherosclerotic cardiovascular disease and diabetes mellitus or obesity: investigation of the potential role in a German inpatient dataset.
- Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation.
- [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
- Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.
- Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
- Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.
- Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.
- Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
- Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Response to Letter].
- Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches.
- Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).
- Tirzepatide in the NHS: The known unknowns of treating obesity at a national scale.
- Weight loss, wakefulness, and what's missing: addressing comorbid insomnia and sleep apnea in the era of tirzepatide.
- Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series.
- Tirzepatide and Cardioprotection in Type 2 Diabetes: Insights From SURPASS-CVOT.
- GLP-1 RA semaglutide for alcohol use disorder: a potential multi-target therapy.
- Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.
- Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
- An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus.
- Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.
- Real-world Physical Activity and Sedentary Time Trends in Patients Undergoing Obesity Treatment: Insights From the All of Us Research Program.
- [Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes].
- [Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].
- A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.
- Corrigendum: Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: a real-world comparative cohort study.
- Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study.
- Could semaglutide be related to increasing the risk of developing a disordered eating?
- More on Semaglutide in Early Type 1 Diabetes. Reply.
- [Nephroprotection in patients with diabetes mellitus].
- [ANMCO Statement: semaglutide in cardio-nephro-metabolic disorders].
- Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis.
- Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.
- Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.
- Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity.
- AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework.
- Glucagon-Like Peptide-1 Receptor Agonists in the Management of Mitochondrial Diabetes in an Adolescent: A Case Report.
- A case of once-weekly basal insulin therapy for a dementia patient with Type 2 Diabetes mellitus and living alone.
- Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review.
- Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats.
- Semaglutide and Musculoskeletal Health: A Mendelian Randomization Study Based on GLP-1 Receptor Expression.
- Semaglutid bessert HFpEF-Herzinsuffizienz.
- Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
- [Effects of liraglutide combined with vitamin D on non-alcoholic fatty liver induced by high fat in mice and its mechanism].
- Semaglutide and Cardiovascular Outcomes.
- Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane.
- Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA.
- Real-World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland.
- Cardiovascular outcomes with tirzepatide in heart failure with preserved ejection fraction associated with obesity.
- Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD.
- A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review.
- Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.
- Semaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring Predictors of Treatment Response.
- Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials.
- Abrupt Smoking Cessation Due to Sensory Aversion Following Tirzepatide Initiation.